Telix Pharmaceuticals Forecast, price target & analysts
Telix Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Telix Pharmaceuticals Classifications & Recommendation:
Telix Pharmaceuticals Price Target
| Target Price | AUD33.91 |
| Price | AUD28.46 |
| Potential |
19.16%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Telix Pharmaceuticals 2026 .
The average Telix Pharmaceuticals target price is AUD33.91.
This is
19.16%
register free of charge
AUD36.00
26.49%
register free of charge
AUD29.14
2.39%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Telix Pharmaceuticals to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Telix Pharmaceuticals stock has an average upside potential 2026 of
19.16%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million AUD | 783.21 | 1,264.89 |
| 55.85% | 61.50% | |
| EBITDA Margin | 11.52% | 14.89% |
| 0.96% | 29.29% | |
| Net Margin | 6.41% | 9.55% |
| 381.24% | 48.97% |
9 Analysts have issued a sales forecast Telix Pharmaceuticals 2025 . The average Telix Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Telix Pharmaceuticals EBITDA forecast 2025. The average Telix Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Telix Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Telix Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share AUD | 0.15 | 0.36 |
| 650.00% | 140.00% | |
| P/E | 84.21 | |
| EV/Sales | 7.99 |
6 Analysts have issued a Telix Pharmaceuticals forecast for earnings per share. The average Telix Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Telix Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Telix Pharmaceuticals...
Current Telix Pharmaceuticals Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WILSONS | Locked ➜ Locked | Locked | Jan 06 2025 |
| WILLIAM BLAIR & COMPANY | Locked ➜ Locked | Locked | Nov 12 2024 |
| BELL POTTER SECURITIES | Locked ➜ Locked | Locked | Nov 06 2024 |
| TD COWEN | Locked ➜ Locked | Locked | Oct 16 2024 |
| TAYLOR COLLISON | Locked ➜ Locked | Locked | Aug 25 2024 |
| BELL POTTER SECURITIES | Locked ➜ Locked | Locked | Aug 21 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
WILSONS: Locked ➜ Locked
|
Jan 06 2025 |
|
Locked
WILLIAM BLAIR & COMPANY: Locked ➜ Locked
|
Nov 12 2024 |
|
Locked
BELL POTTER SECURITIES: Locked ➜ Locked
|
Nov 06 2024 |
|
Locked
TD COWEN: Locked ➜ Locked
|
Oct 16 2024 |
|
Locked
TAYLOR COLLISON: Locked ➜ Locked
|
Aug 25 2024 |
|
Locked
BELL POTTER SECURITIES: Locked ➜ Locked
|
Aug 21 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
